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Abstract
Background: Mesenchymal stem cells derived from adipose tissue (ADSC) are multipotent stem cells, originated
from the vascular-stromal compartment of fat tissue. ADSC are used as an alternative cell source for many different
cell therapies, however in ischemic cardiovascular diseases the therapeutic benefit was modest. One of the reasons
could be the use of autologous aged ADSC, which recently were found to have impaired functions. We therefore
analysed the effects of age on age markers and angiogenic properties of ADSC. Hypoxic conditioning was
investigated as a form of angiogenic stimulation.
Methods: ADSC were harvested from young (1-3 month), adult (12 month) and aged (18-24 month) mice and
cultured under normoxic (20%) and hypoxic (1%) conditions for 48 h. Differences in proliferation, apoptosis and
telomere length were assessed in addition to angiogenic properties of ADSC.
Results: Proliferation potential and telomere length were decreased in aged ADSC compared to young ADSC.
Frequency of apoptotic cells was higher in aged ADSC. Gene expression of pro-angiogenic factors including
vascular endothelial growth factor (VEGF), placental growth factor (PlGF) and hepatic growth factor (HGF) were
down-regulated with age, which could be restored by hypoxia. Transforming growth factor (TGF-b) increased in
the old ADSC but was reduced by hypoxia.
Expression of anti-angiogenic factors including thrombospondin-1 (TBS1) and plasminogen activator inhibitor-1
(PAI-1) did increase in old ADSC, but could be reduced by hypoxic stimulation. Endostatin (ENDS) was the highest
in aged ADSC and was also down-regulated by hypoxia. We noted higher gene expression of proteases system
factors like urokinase-type plasminogen activator receptor (uPAR), matrix metalloproteinases (MMP2 and MMP9)
and PAI-1 in aged ADSC compared to young ADSC, but they decreased in old ADSC. Tube formation on matrigel
was higher in the presence of conditioned medium from young ADSC in comparison to aged ADSC.
Conclusions: ADSC isolated from older animals show changes, including impaired proliferation and angiogenic
stimulation. Angiogenic gene expression can be partially be improved by hypoxic preconditioning, however the
effect is age-dependent. This supports the hypothesis that autologous ADSC from aged subjects might have an
impaired therapeutic potential.
Introduction
Mesenchymal stem cells (MSC) have therapeutic poten-
tial in bone marrow transplantation [1,2], tissue engineer-
ing [3], and cell therapy [4]. Adipose-derived stem cells
(ADSC) are relatively easy to obtain from adipose tissue
and are more frequent than MSC in bone marrow [5].
They represent therefore a promising source for cell
therapy, especially as their isolation is less invasive com-
pared to bone marrow extractions and their expansion in
culture is quite easy [6,7]. The use of MSC from aged
bone marrow donors have been investigated and found
to be less effective in myocardial infarction treatment in
a mouse model probably because of age-induced changes
[8]. For bone marrow derived MSC several studies
analysed age-related changes [9] which were possibly
responsible for the impaired therapeutic impact.
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It is shown that ADSC are able to differentiate into
the classical mesodermal tissues like bone, fat and carti-
lage [10], and it is claimed that they can differentiate
into nerve, cardiomyocytes, hepatocytes and pancreatic
cells [11,12]. ADSC show the same surface markers as
bone marrow derived MSC [13,14]. For either cell type
it is not clear if a small subpopulation of the MSC
might contain additional differentiation capacity [15].
The in vivo potential of these cells is unclear, however
support of neuronal repair [16], osteogenesis [17] and
vasculogenesis were shown [18]. In some studies it was
demonstrated that ADSC could release multiple angio-
genic growth factors and cytokines/chemokines. This
suggest that they may have potential as a useful cell
source for therapeutic angiogenesis [19].
Upon in vitro expansion it was shown that ADSC age
after about 30 population doublings [20] losing adipo-
genic differentiation capacity [21]. One group reported
spontaneous transformation of ADSC. However no
tumors were observed after injection of the cells into
immune-compromised mice [22]. To minimise in vitro
aging effects ADSC and other stem cells have been cul-
tured under reduced oxygen concentrations with mixed
results [23,24]. Differentiation of ADSC seems to be
supported by higher oxygen levels and expansion by low
oxygen levels [25].
Aging negatively affects angiogenesis which is found to
be linked to declined levels of VEGF after ischemic sti-
muli [26]. Therefore, aging-associated changes may con-
stitute a link to cardiovascular diseases and stroke in the
elderly [27]. ADSC are thought to mediate angiogenesis
by releasing growth factors including VEGF, HGF and
basic fibroblast growth factor (bFGF). These factors sti-
mulate endothelial cell division, migration, stromal pro-
genitor cell grafting into the forming vessels. They also
facilitate mobilization of bone marrow endothelial pre-
cursors which participate in neovascularization [28,29].
It is a matter of ongoing discussion whether this prop-
erty is an important part of the regenerative mechanism
of ADSC and is under investigation in several pre-clini-
cal trials [30-33]. As angiogenesis seems to be an impor-
tant factor in tissue remodelling in cell therapies we
investigated the changes of the angiogenesis-related fac-
tor production in aged ADSC.
Hypoxia is known to stimulate the pro-angiogenic
effects of ADSC [28,34], but little is known about the
reactivity of aged ADSC upon a short term exposure
to hypoxia. We therefore investigated ADSC from
young and aged mice under low oxygen. The exact
concentration of oxygen in adipose tissue is not known
and we therefore used the levels of oxygen presumed
for the bone marrow niche [24]. Proliferation and
osteogenic differentiation was therefore tested for
ADSC cultured under normoxia (20%) or hypoxia (1%)
similar to levels found to be beneficial for bone mar-
row derived MSC.
Materials and methods
Chemicals
All chemicals were obtained from Sigma-Aldrich unless
stated otherwise.
Isolation of adipose derived mesenchymal stem cells
C57/Black6 mice were obtained from the University of
Leipzig (Approval for schedule 1 sacrifices were given
by the Regierungspräsidium Leipzig, Germany). ADSCs
were isolated from adipose tissue of mice as described
[6,10,12]. Adipose tissue was washed with PBS, minced
and treated with 200 U/ml collagenase I in DMEM for
1 h at 37°C. Tissue was centrifuged at 1200 g for 5 min
and the supernatant discarded. The pellet containing the
ADSC was lysed to destroy erythrocytes. The material
was then filtered through a sieve, and washed. The cells
were cultured at normoxic conditions (20% of oxygen)
until the experiment starts.
Hypoxia
The day before hypoxia establishment the medium was
replaced with serum-free medium. Then cells have been
cultivated for 48 h under hypoxia (1% of oxygen) or
normoxia (20% of oxygen) conditions. Parameters of
hypoxia modelling were chosen as the most favourable
for inducing changes in gene expression in bone marrow
derived MSC [35,36]. Cell properties were analyzed
immediately after cells had been taken off the hypoxic
incubator.
Cell viability assessment
The number of early apoptotic and dead cells was evalu-
ated with flow cytometry by phycoerythrin conjugated
annexin V (AnnexinV-PE) binding and 7-amino-actino-
mycin (7-AAD) dye accumulation. Cells were removed
from culture plate surface by EDTA in PBS (2 mM, 5 min,
37°C). 100 μl of cell suspension (1-10 × 105 cells/ml) were
incubated with AnnexinV-PE for 20 min and washed with
buffer according to the manufacturing instructions. Then
7-AAD was added for 5 min. Stained cells were analyzed
with cell sorter MoFlo (Dako Cytomation). Cell number at
various apoptosis stages (AnnexinV+ 7-AAD-) and number
of viable (AnnexinV- 7-AAD-) and dead cells (AnnexinV+
7-AAD+) were calculated.
Immunophenotyping of ADSC
Cells were harvested by trypsinisation and stained with
antibodies against CD14, CD19, CD34, CD45, CD73,
CD79, CD90, CD105, NG2 and PDGFRB (diluted 1:100;
4°C; 30 min; Serotec, Oxford, UK). The cells were ana-
lysed using flow cytometry. CD11b antibody (1:100; 4°C;
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30 min; Serotec, Oxford, UK) was used as a negative
control.
Proliferation and osteogenic differentiation of ADSC
Cells were grown in 24 wells at 20,000 ADSC per well.
Proliferation was measured using MTT test (Invitrogen).
For osteogenic differentiation 40,000 ADSC were seeded
in 24 well plates with medium containing 10-8 M dexa-
methasone and 5 μg/ml ascorbic-2-phosphate for 14 days.
Alkaline phosphatise (ALP) quantitation was performed
using a colorimetric assay using r-nitrophenyl phosphate
(r-NPP) as substrate [37]. Ethanol-fixed cells in 24-well
plates were reacted with 200 μl of ALP assay buffer (5 mM
r-NPP, 0.5 mM MgCl2, 0.1% Triton X-100, and 50 mM
TBS, pH 9.5). After incubation at room temperature for
10 min, the absorbance was measured at 405 nm. The
cells were washed, and cell number was determined.
Reactive oxygen species (ROS) and nitric oxide (NO)
Cells were incubated in the dark with 5-(and-6)-chloro-
methyl-2,7-dichlorodihydrofluorescein diacetate acetyl
ester (H2DCF-DA) (50 μM) for 30 min, washed and
analysed with a flow cytometer. Nitric oxide concentra-
tion was measured using standard Griess reagent. 50 μl
supernatant was incubated with 50 μl Griess reagent.
After 5 min incubation at RT, the absorbance was mea-
sured at 560 nm using a tecan plate reader.
Real-time PCR
RNA was isolated according to instructions (RNA/DNA/
Protein Purification Kit, Norgen, Canada). RNA concen-
tration was measured using the NanoDrop (Peqlab).
One μg of total RNA was used to synthesize cDNA with
SuperscriptIII-transcriptase (70 U/1 μg RNA; Invitrogen)
and Oligo(dT)18-Primers (Fermentas, see Table 1 for
the different primer sequences used). For qRT-PCR
(LightCycler 480, Roche) the cDNA was diluted 1:10
and 5 μl added to Express SYBR GreenER qPCR Super-
mix Universal (Invitrogen) Serial dilutions of recombi-
nant standard DNAs containing the analyzed gene
sequences served as controls. Transcript amounts are
normalized to GAPDH, 18S or L7.
Quantitative telomerase activity assay
Cell pellets were resuspended in lysis buffer and analyzed
with qRT-PCR using the quantitative telomerase detec-
tion kit (QTD, Allied Biotech Inc.). Protein concentration
was determined with the BCA Protein assay (Pierce).
Assays were conducted with 1 μg of cell extract, using
0,5 μM telomerase primer TS (5’-AATCCGTCGAGCA-
GAGTT-3’) and 0,5 μM anchored return primer ACX
(5’-GCGCGG(CTTACC)3CTAACC-3’) in 25 μl using
12,5 μl Express SYBR GreenER (Invitrogen). The mix
was incubated for 30 min at RT and used in the qRT-
PCR. The threshold cycle value (Ct) were determined
from semi-log amplification plots and compared with a
standard curve generated from serial dilution of telomer-
ase positive HeLa cell extract. Telomerase activity was
expressed relative to HeLa cells. The negative control
was a heat control incubated for 15 minutes at 85°C.
Telomere length measurement by quantitative PCR
DNA was isolated using the above mentioned kit (Purifi-
cation Kit, Norgen, Canada) and concentration was
Table 1 PCR primers used
Gene Sense strand Antisense strand
c-myc AGTGCTGCATGAGGAGACAC GGTTTGCCTCTTCTCCACAG
p53 TCCCCCGCAAAAGAAAA CTGTAGCATGGGCATCCTTT
oct-4 ACATGAAAGCCCTGCAGAAG AGATGGTGGTCTGGCTGAAC
18s CAGTAAGTGCGGGTCATAAGC ATCCGAGGGCCTCACTAAAC
VEGF-a AGAGCAGAAGTCCCATGAAGTGA TCAATCGGACGGCAGTAGCT
PlGF CCAAGGGGAAGAGGAAGAGGAGTA GCAGGGACGAGTCGGCTAATAA
bFGF GCGCCGCCTTCCCACCAG AGCCAGCAGCCGTCCATCTTCCT
HGF TCATTGGTAAAGGAGGCAGCTATA CTGGCATTTGATGCCACTCTTA
TGFb TGCCCCTATATTTGGAGCCTGGAC GCCCGGGTTGTGTTGGTTGTAGAG
uPA GAATGCGCCTGCTGTCC AGGGTCGCTTCTGGTTGTC
uPAR CGTTACCTCGAGTGTGCGTCCTG AGCCTCGGGTGTAGTCCTCATC
MMP2 AGTTCCCGTTCCGCTTCC AGCCTCGGGTGTAGTCCTCATCC
MMP9 GCGGTGTGGGGCGAGGTG CCAGGGGGAAAGGCGTGTGC
ENDS AGTTTGGTCTTGCTGCTGGTG AAGTCCCGGAAGAAGAGTTTTG
TBS1 GCGCGGAGCTGGATGTA AATGTCTTCTGGGGTGGTTC
PAI-1 GCTTCATGCCCCACTTCTTCAA ACCAGGCGTGTCAGCTCGTCTA
L7 CTCCGTCTGCGGCAGATC CAGCATGTTAATTGAAGCCTTGTT
GAPDH GACCCCTTCATTGACCTCAACTAC TGGTGGTGCAGGATGCATTGCTGA
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measured using the nanodrop (Peqlap). Telomere length
was measured and analyzed by qRT-PCR [38]. PCR was
performed in a Light Cycler 480 (Roche).
Carbonyl-ELISA
Protein carbonyls were measured according to Buss
et al. [39] with modifications described by Sitte et al.
[40]. The absorbance was determined with a multiwell
plate reader using a detection wavelength of 492 nm.
GpX activity
Cells were lysed in a buffer and the proteins isolated.
After measuring the protein concentration using BCA,
GPX activity was measured according to instructions
provided by the company (Cayman Chemical).
In vitro tube formation assay
Effect of young and aged ADSC conditioned medium in
vitro on capillary-like tubes formation on Matrigel was
evaluated. Conditioned medium was collected from
ADSC of young (1.5-2 months old) and aged (18
months old) mice cultured in hypoxic and standard con-
ditions. Human umbilical vein endothelial cells
(HUVEC) at the 2-4th passages were seeded in 48-well
plates coated with growth factor reduced Matrigel (BD
Bioscience) in concentration 2 × 104 cells per well.
HUVEC growth medium was supplemented with condi-
tioned medium in ratio 1:1. At least, two wells were
used for each sample of conditioned medium. HUVEC
serum-free growth medium was utilized as negative con-
trol; HUVEC growth medium with 20% FBS served as
positive control. Plates were placed into CO2-incubator
at 37°C and capillary-like structures were assayed in
24 h under the light microscope (Leica, Germany). Total
length of tubular structures was counted in 5 random
fields of view (objective 10×) with MetaMorph 5.0 soft-
ware (Universal Imaging).
Data analysis
Statistical analysis was performed using SigmaStat 9.0. If
normality of data was confirmed (according to the Sha-
piro-Wilkson test) comparison of independent groups
was performed by Student t-test, if not - by one-way
analysis of variance (Cruscal-Wolles ANOVA) and
Mann-Whitney U-criteria. Multiple comparisons were
made using Tukey’s test. Values were expressed as mean
+/- standard deviation for normally spread data and as
median (25, 75 percentile) for not normal data. Data
was considered significantly different when p < 0.05.
Results
ADSC characteristics
Analyzing of ADCS immunophenotype by flow cytome-
try showed that cells were positive for CD73 (83 ± 8%),
CD90 (>95%) and CD105 (>95%) with no or low
expression of CD14 (<10%), CD19 (<10%), CD34 (<5%),
CD45 (<1%), CD79 (<10%). This expression profile is
normal for MSC according to the International Society
for Cellular Therapy Statement of minimal criteria for
defining MSC [41]. ADSC also expressed pericyte mar-
kers like neural glial antigen (NG2) and platelet derived
growth factor receptor beta (PDGFRB), which stayed in
agreement with a conception of this type of progenitors
as perivascular cells (data not shown) [42,43].
ADSC derived from young mice proliferated signifi-
cantly faster than those from old mice (Figure 1a).
Young ADSC under hypoxic conditions (1%) prolifer-
ate significantly slower. Aged ADSC under hypoxic
conditions did not decrease their proliferation rate
(Figure 1a).
Measurements of annexin V binding and 7-AAD accu-
mulation by flow cytometry showed that number of
apoptotic cells was 3-fold higher in aged ADSC. Both
young and aged ADSC cultivation under hypoxia neither
induce cell death by apoptosis nor reduce their general
viability (Figure 1b).
Cell senescence is accompanied with changes in cell
cycle regulators. C-myc is found to be down-regulated
in aged ADSC in normal and hypoxic treated cultures
(Figure 1c). Surprisingly we find the same decrease in
the expression pf p53 (Figure 1d). Analyzing the osteo-
genic differentiation of ADSC we showed that level of
ALP per cell in ADSC cultured in osteogenic induction
medium was higher in aged cells compared to young
(Figure 2a).
We measured ROS and NO levels because they are
both important signal molecules for osteogenic differen-
tiation of ADSC and a marker of cell quality. ROS levels
as well as NO production were significantly increased in
aged ADSC (Figure 3a, b). The levels of ROS were sig-
nificantly down-regulated in aged ADSC under hypoxic
conditions; however they were not affected in young
ADSC (Figure 3a).
Increasing oxidative stress is linked to induction of
differentiation. We therefore measured therefore the
level of the stemness gene oct4 which is expressed in
MSC. Aged ADSC oct 4 expression is significantly
downregulated for normal but not for ADSC under
hypoxia (Figure 2c).
The loss of proliferation due to age is often linked to
telomere shortening in somatic cells. In ADSC we found
a dramatic shortening of telomere length due to the age
of the mice. The short term culturing under hypoxic
conditions did not affect telomere length (Figure 2c).
Increased ROS production might be linked to declining
antioxidant activities. Therefore we measured the activ-
ity of glutathione peroxide (GPx) activity, arguably one
of the most important antioxidative enzymes. GPx activ-
ity decreased with age in ADSC. In aged ADSC cultures
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under hypoxic conditions the activity decreased even
further (Figure 3c). Levels of carbonyls were significantly
down-regulated in aged ADSC under normoxic and
hypoxic conditions (Figure 3d). Interestingly we
observed increased carbonyl levels in young ADSC but
decreased carbonyl levels in aged ADSC under hypoxia.
Angiogenesis
Expression of several genes involved in angiogenesis was
analysed in ADSC of different age. To evaluate the
dynamic of age-changes in gene expression we included
an additional group of 24 months old animals.
Gene expression of VEGF, a pro-angiogenic acting
cytokine, declined significantly in ADSC from 24 month
old mice and was unchanged in 18 month old mice
compared to the 3 month old group. Hypoxia signifi-
cantly stimulated the production of VEGF in all mea-
sured groups; however the effect declined with
increasing age (Figure 4a).
PlGF, another pro-angiogenic factor, already was
down-regulated significantly in ADSC from 18 month
old mice and also in ADSC from 24 month old mice.
Hypoxia increased mRNA content of PlGF in all groups.
However the size of the changes induced by hypoxia in
ADSC declined rapidly with age (Figure 4b).
Interestingly, gene expression of HGF, an important
angiogenic and anti-apoptotic factor, was significantly
higher in ADSC from 18 and 24 month old mice
Figure 1 Proliferation and viability analysis of ADSC. Proliferation was measured in young and aged (12 month) ADSC cells cultured under
normoxia or hypoxia for 48 h before the test (A). Level of cell death was measured using a double staining of 7-AAD and annexinV quantified
by flow cytometry (B). Expression of c-myc (C) and p53 (D) were measured using qRT-PCR. Results are means of 5 different animals and
considered significantly changed when: * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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compared to young ADSC, but aged cells showed worse
response to hypoxia, which resulted in the similar level
of HGF in young and aged ADSC cultured under
hypoxic conditions (Figure 4c).
Gene expression of TGF-b1 were similar in ADSC
from young and aged animals but did increase signifi-
cantly in old ADSC (Figure 3d). Hypoxia did not alter
expression levels in young or aged ADSC but declined
TGF-b1 expression in old ADSC.
Factors regulating migration and chemotaxis of stem
cells like urokinase (uPA) and its receptor (uPAR) as
well as MMPs are involved in angiogenesis by degrading
the matrix. Expression of MMP2 and MMP9 signifi-
cantly increased in aged ADSC (18 month old mice)
compared to young ADSC but declined in old ADSC.
In hypoxic conditions MMPs expression level could be
decreased significantly in young and aged ADSC but not
in old ADSC (Figure 5a, b). uPAR expression signifi-
cantly increased in aged ADSC and hypoxia stimulated
its expression only in young ADSC (Figure 5c). uPA
expression declined significantly in old ADSC compared
to young ADSC. Hypoxia inhibited uPA expression in
aged ADSC but this effect did not reach significance in
young ADSC (Figure 5d). ADSC of the oldest group of
mice did not react to the hypoxia stimulus (Figure 5).
Expression of anti-angiogenic factors, including PAI-1,
ENDS and TBS1 was higher in aged ADSC compared to
young ADSC, but the elevation was significant only for
PAI-1. Cell culture under hypoxic conditions inhibited
expression of all anti-angiogenic factors (Figure 6a, b, c).
Figure 2 Osteogenic differentiation, expression of oct4 and telomere length in ADSC. Ability of ADSC for osteogenic differentiation in the
osteogenic induction medium was analyzed using ALP measure (A). Expression of oct4 (B) and changes in telomere length (C) were
investigated using qRT-PCR. Results are means of 5 different animals and considered significantly changed when: * = p < 0.05, ** = p < 0.01,
*** = p < 0.001.
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To evaluate the summary of angiogenic factors pro-
duced by ADSC we examined the effect of conditioned
medium from cells cultured under different conditions
on the capillary-like tube formation (Figure 7a, b). Tube
formation assay showed that more extensive network of
capillary-like structures on Matrigel was formed in the
presence of conditioned medium from young ADSC as
compared with aged ADSC (p = 0.01). Conditioned
medium from both types of cells cultured under hypoxia
better stimulated formation of capillary-like structures
than the medium from cells cultured under normoxic
conditions (p = 0.012 for young ADSC and p = 0.074
for aged ADSC), but difference in this elevation between
young and aged ADSC was insignificant (13 ± 3% for
young ADSC vs. 11 ± 4% for aged ADSC, p = 0.49).
Discussion
Adipose tissue derived MSC are a good alternative
source to bone marrow derived MSC for cell therapy
because of their easy access and high cell numbers.
However they seem to undergo similar age-induced
changes as bone marrow derived MSC [44]. Here we
tested the effect of short-term hypoxic conditioning dur-
ing cultivation of young and aged MSC from adipose
tissue. Hypoxic conditioning has shown beneficial effects
in bone marrow derived MSC, increasing their angio-
genic properties [36].
We found more apoptotic cells among aged ADSC
compared to young ADSC which is in agreement with
higher ROS and NO production and down-regulation
of antioxidative defence enzyme GPx in these cells.
Figure 3 Oxidative damage of ADSC. ROS are measured using H2DCF-DA staining of ADSC and quantification in a flow cytometer (A). NO
concentration was measured using standard Griess reagent (B). Expression level of glutathione dismutase gene was measured using qRT-PCR
(C). The level of oxidative damage was investigated using ELISA in young and aged ADSC (normoxia and hypoxia) (D). Results are means of 5
different animals and considered significantly changed when: * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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In aged ADSC the mRNA expression level of p53 was
down-regulated. On the contrary, in rat and human
aged bone marrow derived MSC, we found an
increased p53 protein content [44]. Other reported
increased p53 gene expression levels in human aged
bone marrow MSC [45]. Another factor involved in
proliferation but also senescence is c-myc a tumor pro-
moter gene. We found that in aged ADSC c-myc is
down-regulated (Figure 1c) as it had been reported for
other senescent cell types [46]. The third part of
ADSC proliferation is the maintenance of self-renewal,
and here we analysed Oct4 expression which is known
to be expressed in undifferentiated MSC. We found a
small reduction of Oct4 gene expression with age.
A loss of stem cell characteristics has been described
for MSC from different species and locations. Oct4
expression was also found to be down-regulated in
aged mouse satellite stem cells and in hESC cells
cultured with serum from old mice [47].
All of these features were accompanied with telomere
shortening. This was also for human MSC derived from
different age groups [48]. ADSC derived from aged mice
showed reduced proliferation potential compared to
young ADSC as it was also reported for MSC from
bone marrow [44] and did not react to the lower oxygen
as was observed for aged rat bone marrow derived MSC
[23]. A similar loss of responsiveness to a culture stimu-
lus was observed in aged bone marrow MSC towards a
temperature change [49]. It seems that aged MSC are
less able to adapt to environmental changes and lose a
part of their stem cell potential.
Angiogenesis during regeneration
MSC can participate in regeneration via paracrine
effects. MSC release different factors including growth
factors, immune-modulatory factors and chemo-attrac-
tants involved in angiogenesis [50]. Angiogenesis is
thought to be one of the mechanisms by which MSC
Figure 4 Effect of age and hypoxic stimulation on pro-angiogenic factors gene expression. Expression levels of VEGF (A), PGF (B), HGF
(C) and TGF-beta (D) were measured using qRT-PCR. Animal groups consisted of young (1-3 month, 16 animals), aged (18 months, 9 animals)
and old mice (24 months, 7 animals). Results are means of different animals (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
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can improve heart remodelling [51] or protect from
limb ischemia [52]. MSC interact with endothelial cells
and support the re-establishment of a blood supply,
which is fundamental for tissue repair. Angiogenesis
declines with age [53]. Therefore, we compared ADSC
derived from young (1-3 months), adult (18 months)
and aged (24 months old) mice in their ability to pro-
duce angiogenic growth factors.
We found that older ADSC showed impaired angio-
genic properties in in vitro assays. VEGF and PlGF
expression levels in young ADSC exceeded the corre-
sponding levels in aged ADSC. Higher expression of
VEGF was also observed in bone marrow derived MSC
from young rats compared to 24-26 weeks old rats [23].
Decline of VEGF and TGFb expression as well as signifi-
cant increase of anti-angiogenic factor TBS2 were found
in (6 compared to 24 month) mice. This went along
with decreased angiogenesis in these animals [54].
HGF expression increased in aged ADSC. This up-
regulation might be explained by a marked autocrine
stimulation of ADSC by interleukin 1. Such a mechan-
ism was demonstrated in fibroblasts derived from skin
of aged donors [55].
Genes involved in matrix remodelling like uPAR, MMP
2 and MMP 9 were higher in ADSC from 18 month old
mice. This point toward an enhanced invasive and migra-
tory capacity of mature progenitors which has not been
described before. In the oldest ADSC group, however it
declined, which might be linked to impaired repair pro-
cesses as found in many older organism.
Genes inhibiting angiogenesis like TBS1 and PAI-1
were up-regulated with age. ENDS did not follow this
trend. Endostatin, a collagen degradation product, seems
to counteract many VEGF induced effects including
VEGF induced endothelial migration and neovasculari-
sation [56]. Nothing is known about the age-related
Figure 5 Effect of age and hypoxic stimulation on urokinase system factors gene expression. Expression levels of MMP2 (A), MMP9 (B),
uPAR (C) and uPA (D) were measured using qRT-PCR. Animal groups consisted of young (1-3 month, 16 animals), aged (18 months, 9 animals)
and old mice (24 months, 7 animals). Results are means of different animals (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
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Figure 6 Effect of age and hypoxic stimulation on anti-angiogenic factors gene expression. Expression levels of ENDS (A), PAI (B) and
TBS1 (C) were measured using qRT-PCR. Animal groups consisted of young (1-3 month, 16 animals), aged (18 months, 9 animals) and old mice
(24 months, 7 animals). Results are means of different animals (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
Figure 7 Effect of age and hypoxic stimulation on capillary-like tube formation in the presence of conditioned medium from ADSC.
Morphology of tubes formed by endothelial cells on matrigel incubated with either medium alone, FBC containing medium or ADSC
conditioned medium (A). Summary length of the formed tubes was quantified (B) (* = p < 0.05).
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secretion of endostatin by mesenchymal stem cells.
PAI-1 is a downstream target of p53 and is involved in
regulating growth factor signalling [57]. In the liver
and adipose tissues of rats PAI-1 was up-regulated in
24 month old rats compared to 3 month old rats [58].
An increase in PAI-1 was also found in senescent
human fibroblasts [59].
TBS1, a microcellular protein and an autocrine factor
for vascular smooth muscle cells, is constituently
expressed in human MSC [60]. TBS-1 is up-regulated
in the fibroblasts of 24 month old rats compared to
3 month old rats [61], which correlates with our results
in mouse ADSC.
To check the angiogenic effect of the combination of
factors secreted by ADSC we used an in vitro tube for-
mation assay, which showed reduced tube formation in
the presence of conditioned medium with secreted fac-
tors from aged ADSC. Similar results were obtained
with bone marrow derived MSC [23] and for young
human ADSC [62]. In these studies, however the differ-
ence was quite modest.
Hypoxia and angiogenesis
Tissue damage is often linked to ischemia. That is why
it is important to understand the reaction of ADSC
towards hypoxia but also because hypoxia can be used
to stimulate MSC. Hypoxic conditioning of human
ADSC can increase angiogenesis via secreted factors
[28,34,63], however nothing is known about this feature
in ADSC derived from old donors. The most intensively
studied mechanism of cell responses to hypoxia is HIF-1
alpha transcription factor activation. Activation of HIF-1
results in increased gene expression of angiogenesis sti-
mulating factors such as VEGF, angiopoietin, PDGFB,
TGFb1 and stromal derived factor 1 [64].
Grafting of hypoxia preconditioned bone marrow
derived MSC improves their viability in damaged heart
tissue and increases their capacity to stimulate blood
vessel growth [65]. In addition hypoxia leads to
enhanced MSC migration and formation of capillary-like
structures in vitro [66].
No data on the effect of oxygen on the matrix
remodelling genes uPAR and uPA in MSC from bone
marrow are available. It was shown that gene expression
of angiogenesis inhibitors including endostatin and PAI-1
were down-regulated in hypoxic human stromal cells [67]
as it was found in our ADSC cells.
In summary, we found that hypoxia stimulated gene
expression of pro-angiogenic factors and blocked gene
expression of anti-angiogenic factors in ADSC. The
effect was smaller in ADSC from older animals. Jiang et
al. showed that bone marrow MSC from young rats
were superior responders to anoxia both during
the acute phase after exposure to anoxia and upon
re-oxygenation for 48 hours compared to older rats [23].
Rivard et al. suggested that in aged donors impaired
regulation of VEGF in response to hypoxia is due to
declined hypoxia inducing factor 1 alpha activity [68].
Conclusion
Taken together our data shows that aged mice ADSC
show impaired proliferation and stem cell characteris-
tics, decreased angiogenic properties and a loss of
stimulation by hypoxia suggest that short term hypoxic
conditioning of ADSC is still effective in aged animals
and might therefore be considered useful in therapies
using MSC.
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